On January 14, 2015, China Food and Drug Administration (CFDA) approved the production of the first inactivated poliomyelitis vaccine made from Sabin strains (Sabin IPV) (single component), which was researched and developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences. The vaccine is used for preventing children from infecting poliovirus by injection. The launch of the Sabin IPV will play a critical role for the eradication of poliomyelitis in China.